Mebendazole potentiates radiation therapy in triple-negative breast cancer

Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancers to treat, despite aggressive treatment approaches including radiation therapy. In this study, a common antihelminthic drug, mebendazole (MBZ) is shown to deplete breast cancer stem cells in a TNBC model and act as a potent radiosensitizer in vitro and in vivo. These results strongly support the repurposing of MBZ as a radiosensitizer for the treatment of TNBC patients in combination with radiation therapy.

https://ift.tt/2oLGM3T